四环医药旗下轩竹生物制药在2026年美国癌症研究协会（AACR）年会上，公布了其创新药物迪罗唑克（Dirozalkib）用于治疗ALK阳性非小细胞肺癌（NSCLC）的III期临床试验关键数据。
此次公布的数据备受业界关注，为ALK阳性非小细胞肺癌患者提供了新的潜在治疗选择。
四环医药旗下轩竹生物制药在2026年美国癌症研究协会（AACR）年会上，公布了其创新药物迪罗唑克（Dirozalkib）用于治疗ALK阳性非小细胞肺癌（NSCLC）的III期临床试验关键数据。
此次公布的数据备受业界关注，为ALK阳性非小细胞肺癌患者提供了新的潜在治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.